Investing in biotechnology stocks is complex due to the science behind the company’s drug candidates. They can be difficult to trade because these stocks are highly volatile, with double-digit moves in both directions a common occurrence.
However, biotech stocks offer a compelling risk-rewa.... |
Good MorningThe Federal Reserve’s quarter-point rate cut and signal of two more reductions this year sent Treasury yields lower and kept equities near record highs. The Dow rose 0.6%, while the S&P 500 and Nasdaq slipped slightly as investors weighed the dovish shift against growth concerns. Defensive stocks outperformed tech late in the session.
Tech and AI leaders remained in focus after upgrades highlighted strength in AI names, with NVIDIA leading momentum despite China export curbs. Meta is unveiling AI-powered glasses, and Amazon pledged $1 billion to boost wages and cut healthcare costs. Meanwhile, StubHub’s IPO fell 6% below its $23.50 debut price, underscoring mixed market sentiment. Featured: Sell these "safe" blue chips immediately (Ad) 
| Healthcare | |
Investing in biotechnology stocks is complex due to the science behind the company’s drug candidates. They can be difficult to trade because these stocks are highly volatile, with double-digit moves in both directions a common occurrence.
However, biotech stocks offer a compelling risk-rewa... Read the Full Story |
| From Our Partners | | Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief.
It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live. | | Watch the full story and see the verified track record for yourself |
| Industrials | |
A recent Buy upgrade from Melius Research has sharpened investor focus on GE Vernova (NYSE: GEV), accompanied by a new, optimistic $740 price target. This signal from Wall Street is underpinned by a powerful catalyst transforming the energy sector: the explosive growth of artificial intelligence... Read the Full Story |
| Technology | |
Macro is often an intimidating term for retail investors, as it encompasses everything from interest rates to inflation, employment, and global capital flows. However, macroeconomic forces are the true drivers behind every major market cycle.
Not Federal Reserve (the Fed) rate cuts or hikes, not ... Read the Full Story |
| From Our Partners | | Moderna's stock doubled in a single day after its cancer vaccine hit key Phase 3 goals, and Merck jumped too. But according to a former Steve Cohen fund manager, the next big opportunity is not Moderna or Merck.
It is a different kind of company tied to a technology already backed by Elon Musk, Sam Altman, Jeff Bezos, and Peter Thiel. Nvidia's Jensen Huang says it will have a dramatic impact on daily life, while Anthropic's CEO believes it could unlock a century of medical progress in just ten years.
Nature Magazine estimates its potential value at $367 trillion globally, and it is already rolling out across the United States. | | Click here to learn about this new era of medical technology |
| Consumer Discretionary | |
Dave & Buster’s (NASDAQ: PLAY) FQ2 earnings report was no blowout with tepid revenue growth and a significant contraction in earnings.
However, it still highlights the company’s strengths and the significant potential for recovery, which has greatly improved. The company found i... Read the Full Story |
| Consumer Discretionary | |
Retail giant Nike Inc. (NYSE: NKE) and its stock have to be one of the industry's horror stories from recent years. After soaring through the pandemic, shares have since fallen in a near-continuous slide that's wiped out more than 60% of their value, while the major indices have been printing re... Read the Full Story |
| From Our Partners | | Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required.
Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away. | | Discover the gold income fund before the next payout date |
| Communication Services | |
Tech giant Oracle (NYSE: ORCL) recently put out an earnings report that left many market observers in awe. The company’s Q1 fiscal 2026 sales and adjusted earnings per share weren’t what impressed; Oracle actually missed estimates on both figures. However, Oracle’s outlook was ... Read the Full Story |
| Technology | |
Less than a week after providing a highly encouraging financial update that sent shares soaring, chip giant Broadcom (NASDAQ: AVGO) made another huge move.
On Sept. 10, shares surged by approximately 9.8%, eclipsing the 9.4% up-move seen after Broadcom’s Sept. 4 earnings report.
This all... Read the Full Story |
| Technology | |
The changes to MarketBeat’s screen for Most Upgraded Stocks posted since the FQ2 earnings reports were released are significant. These are perhaps the most critical changes in many quarters, as the AI market leaders are back in the analysts’ favor.
Stocks in the ranking include five o... Read the Full Story |
| Technology | |
A landmark $6.3 billion deal with AI chip leader NVIDIA (NASDAQ: NVDA) recently sent shares of CoreWeave (NASDAQ: CRWV) soaring, crystallizing the company’s crucial role in the artificial intelligence (AI) boom. The market’s excitement reflects a growing understanding of a classic in... Read the Full Story |
| Technology | |
CrowdStrike Holdings Inc. (NASDAQ: CRWD) is in a quiet period of sorts. The company won’t report earnings until the end of November, meaning investors have to get through what are notoriously sluggish months for stocks with no fuel beyond headline news to push CRWD stock higher.
Fortunate... Read the Full Story |
| Thursday's Early Bird Stock Of The Day argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands. | Should I Buy argenex Stock? ARGX Bull and Bear Case Explained
These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of argenex was last updated on Wednesday, August 26, 2026 at 6:28 PM.
argenex Bull Case -
The company recently reported strong earnings, with earnings per share significantly exceeding analyst expectations, indicating robust financial performance.
-
argenx SE has a high net margin, showcasing its efficiency in converting revenue into profit, which is attractive for potential investors.
-
With a market capitalization of approximately $63.78 billion, argenx SE is positioned as a major player in the biotechnology sector, suggesting stability and growth potential.
-
The current stock price is around $1,000, reflecting a strong market position and investor confidence in the company's future prospects.
-
Analysts have a consensus rating of "Moderate Buy" for argenx SE, with many recent upgrades to target prices, indicating positive sentiment in the market.
argenex Bear Case -
The stock has shown volatility, with a significant range between its one-year low and high, which may pose risks for conservative investors.
-
Despite strong earnings, the high P/E ratio suggests that the stock may be overvalued, which could lead to corrections in the future.
-
There is a substantial reliance on the success of its antibody-based therapeutics, which can be unpredictable and subject to regulatory challenges.
-
Recent institutional trading activity indicates mixed sentiment, with some investors significantly increasing their stakes while others may be cautious.
-
The biotechnology sector can be highly competitive and subject to rapid changes, which may impact argenx SE's market position and growth trajectory.
| | View Today's Stock Pick |
|
| |
|
|
